

TITULO	REVISTA	FI	Q	DOI	Pubmed Id	UT (Unique WOS ID)
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis	ONCOLOGY AND THERAPY			10.1007/s40487-021-00182-0	35032007	WOS:000742566400001
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience	CANCERS	6,575	Q1	10.3390/cancers14112673	35681653	WOS:000808658000001
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGICAM Study	CANCERS	6,575	Q1	10.3390/cancers14194705	36230628	WOS:000866703700001
Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence	EUROPEAN JOURNAL OF INTERNAL MEDICINE	7,749	Q1	10.1016/j.ejim.2022.02.020	35227541	WOS:000866517600009
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer	FRONTIERS IN ONCOLOGY	5,738	Q2	10.3389/fonc.2021.827625	35223459	WOS:000761124100001
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics	BMC CANCER	4,638	Q2	10.1186/s12885-022-09830-8	35790916	WOS:000820999500002
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastroesophageal adenocarcinoma? Data from the AGAMENON-SEOM registry	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY	4,322	Q2	10.1007/s00432-022-04294-6	36042046	WOS:000847626000006
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis	CLINICAL & TRANSLATIONAL ONCOLOGY	3,340	Q3	10.1007/s12094-022-02998-2	36417083	WOS:000886812200001
Efficacy and safety of FOLFIRI/afibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen	PLOS ONE	3,752	Q2	10.1371/journal.pone.0269399	35657983	WOS:000843567600082
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting	SCIENTIFIC REPORTS	4,996	Q2	10.1038/s41598-022-18871-9	36028552	WOS:000846571700030
Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus	CLINICAL & TRANSLATIONAL ONCOLOGY	3,340	Q3	10.1007/s12094-022-02822-x	35349041	WOS:000774594000001
Liquid biopsy: the value of different bodily fluids	BIOMARKERS IN MEDICINE	2,498	Q4	10.2217/bmm-2021-0370	35073730	WOS:000746485700001
Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors-Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?	CANCERS	6,575	Q1	10.3390/cancers14143323	35884384	WOS:000831709800001
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer	CLINICAL & TRANSLATIONAL ONCOLOGY	3,340	Q3	10.1007/s12094-021-02767-7	34997474	WOS:000740217300002
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study	EUROPEAN JOURNAL OF CANCER	10,002	Q1	10.1016/j.ejca.2022.03.006	35429901	WOS:000819787600002
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients	CLINICAL LUNG CANCER	4,840	Q2	10.1016/j.clc.2021.07.008	34393061	WOS:000799215100018
SEOM-GEICO clinical guidelines on endometrial cancer (2021)	CLINICAL & TRANSLATIONAL ONCOLOGY	3,340	Q3	10.1007/s12094-022-02799-7	35312947	WOS:000771319500001
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)	CLINICAL & TRANSLATIONAL ONCOLOGY	3,340	Q3	10.1007/s12094-022-02803-0	35258806	WOS:000766134500001
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry	ESMO OPEN	6,883	Q1	10.1016/j.esmoop.2022.100514		WOS:000886288700001
The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report	ESMO OPEN	6,883	Q1	10.1016/j.esmoop.2022.100572	36108559	WOS:000860019900005
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy	JOURNAL FOR IMMUNOTHERAPY OF CANCER	12,469	D1	10.1136/jitc-2022-005320	36171009	WOS:000864136800005
Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGICAM study	EUROPEAN JOURNAL OF CLINICAL NUTRITION	4,884	Q2	10.1038/s41430-022-01101-w	35194197	WOS:000759313900003
Venous Thromboembolism In Cancer Patients: From Evidence to Care	CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS	3,512	Q3	10.1177/10760296221098717	35538861	WOS:000798264000001

Original Research Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations	EUROPEAN JOURNAL OF CANCER	10,002	Q1	10.1016/j.ejca.2022.02.014	35307254	WOS:000807170000003
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial	ANNALS OF ONCOLOGY	51,769	D1	10.1016/j.annonc.2021.11.010	34839016	WOS:000746376800008
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)	JOURNAL OF CLINICAL ONCOLOGY	50,739	D1	10.1200/JCO.21.02660	35576508	WOS:000974782000001